Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
- Conditions
- Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)
- Interventions
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2019-06-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 457
- Registration Number
- NCT01922102
- Locations
- 🇹🇭
Novartis Investigative Site, Nakornphathom, Thailand
Aliskiren Study of Safety and Efficacy in Senior Hypertensives
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2015-04-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01922141
Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2015-01-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 152
- Registration Number
- NCT01922271
- Locations
- 🇩🇪
Novartis Investigative Site, Sonneberg, Germany
Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2015-10-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 498
- Registration Number
- NCT01922089
- Locations
- 🇬🇧
Novartis Investigative Site, Nuneaton, United Kingdom
Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- First Posted Date
- 2013-08-12
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 4822
- Registration Number
- NCT01920711
- Locations
- 🇬🇧
Novartis Investigative Site, Wrexham, United Kingdom
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
- Conditions
- Pemphigus Vulgaris
- Interventions
- Biological: OfatumumabBiological: Placebo
- First Posted Date
- 2013-08-12
- Last Posted Date
- 2019-06-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 35
- Registration Number
- NCT01920477
- Locations
- 🇷🇴
Novartis Investigational Site, Cluj-Napoca, Romania
A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)
- First Posted Date
- 2013-08-08
- Last Posted Date
- 2016-01-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT01919229
- Locations
- 🇺🇸
University of California at Los Angeles UCLA SC, Los Angeles, California, United States
🇺🇸Massachusetts General Hospital SC-9, Boston, Massachusetts, United States
🇺🇸University of Texas/MD Anderson Cancer Center Dept of MD Anderson (8), Houston, Texas, United States
Effect of LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2015-02-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT01915849
- Locations
- 🇺🇸
Novartis Investigative Site, Chula Vista, California, United States
Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
- Conditions
- Cushings Disease
- Interventions
- First Posted Date
- 2013-08-02
- Last Posted Date
- 2020-09-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 68
- Registration Number
- NCT01915303
- Locations
- 🇺🇸
Oregon Health and Science University SOM230B2411, Portland, Oregon, United States
🇹🇷Novartis Investigative Site, Pendik / Istanbul, Turkey
🇺🇸University of Alabama at Birmingham The Kirklin Clinic, Birmingham, Alabama, United States
Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma
- Conditions
- Severe IgE-mediated Asthma
- Interventions
- First Posted Date
- 2013-07-31
- Last Posted Date
- 2019-07-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 112
- Registration Number
- NCT01912872
- Locations
- 🇲🇽
Novartis Investigative Site, Mérida, Yucatán, Mexico